This study was performed to determine whether modulation of light delivery
could improve tumour kill in photodynamic therapy (PDT) of brain tumours, a
s optimal dosimetry has not been fully established. One hundred and sixty-f
ive adult Wistar rats were treated, of which 70 had an implanted C6 cerebra
l glioma. Haematoporphyrin derivative (HpD) was injected at doses between 0
and 20 mg/kg, 24 h prior to irradiation with 630 nm laser light. The total
energy dose was Varied from 0 to 1200 J/cm(2), with fluence rates of 625,
3125 or 9375 mW/cm(2). In some studies, the light delivered at 3125 mW/cm(2
) was divided into 10 fractions of approximately 13 s, with refractory inte
rvals of 60 s. The most striking finding was that HpD was much more potent
than previously reported. All doses greater than 1.0 mg/kg resulted in norm
al brain damage with light doses above 50 J/cm(2). However, at 1.0 mg/kg, s
ignificant normal injury was not apparent until 1200 J/cm(2). Failure of dr
ug-light dose reciprocity indicated that photobleaching occurred, protectin
g normal tissue. Selective tumour kill was observed to 2.2 mm depth (SE +/-
0.44 mm). Using lower power or fractionated light did not improve tumour k
ill and normal tissue injury occured with fluence rates of 9375 mW/cm(2). I
n conclusion, the doses of HpD currently used in clinical brain tumour tria
ls may be too high to achieve selective tumour kill. Higher light fluence r
ates allowed shorter intraoperative irradiation times with no loss of effic
acy. Photodynamic therapy continues to demonstrate potential as an effectiv
e treatment for local control of cerebral lesions.